Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41

Antiviral Research

Volumn 80, Issue 1, 2008, Pages 71-76

  Nishikawa, Hiroki ^a   Kodama, Eiichi ^a   Sakakibara, Ayako ^a   Fukudome, Ayako ^a   Izumi, Kazuki ^a   Oishi, Shinya ^a   Fujii, Nobutaka ^a   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Alkaline phosphatase; ELISA; Fusion; Gp41; HIV 1; Screening

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBODY CONJUGATE; ANTIVIRUS AGENT; DIMETHYL SULFOXIDE; ENFUVIRTIDE; GLYCOPROTEIN GP 41; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS FUSION INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPTAD REPEAT; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE FUSION; MOLECULAR INTERACTION; NONHUMAN; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; PH; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ASSAY; REPRODUCIBILITY; SCREENING; TECHNIQUE; VIRION; VIRUS ATTACHMENT; VIRUS ENTRY;

ALKALINE PHOSPHATASE; AMINO ACID SEQUENCE; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MEMBRANE FUSION; REPETITIVE SEQUENCES, AMINO ACID; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 50049102385     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.05.006     Document Type: Article

References (43)

1. Aquaro S., D'Arrigo R., Svicher V., Perri G.D., Caputo S.L., Visco-Comandini U., Santoro M., Bertoli A., Mazzotta F., Bonora S., Tozzi V., Bellagamba R., Zaccarelli M., Narciso P., Antinori A., and Perno C.F. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J. Antimicrob. Chemother. 58 (2006) 714-722
2. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5698-5703
3. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., and De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6132-6136
4. Bewley C.A., Louis J.M., Ghirlando R., and Clore G.M. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 277 (2002) 14238-14245
5. Bosch B.J., Martina B.E., Van Der Zee R., Lepault J., Haijema B.J., Versluis C., Heck A.J., De Groot R., Osterhaus A.D., and Rottier P.J. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 8455-8460
6. Cabrera C., Marfil S., García E., Martinez-Picado J., Bonjoch A., Bofill M., Moreno S., Ribera E., Domingo P., Clotet B., and Ruiz L. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 20 (2006) 2075-2080
7. Cai L., and Gochin M. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51 (2007) 2388-2395
8. Calmy A., Pascual F., and Ford N. HIV drug resistance. N. Engl. J. Med. 350 (2004) 2720-2721
9. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
10. De Clercq E., Yamamoto N., Pauwels R., Balzarini J., Witvrouw M., De Vreese K., Debyser Z., Rosenwirth B., Peichl P., Datema R., et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38 (1994) 668-674
11. Dodt J., Schmitz T., Schäfer T., and Bergmann C. Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence. FEBS Lett. 202 (1986) 373-377
12. Eckert D.M., and Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70 (2001) 777-810
13. Fätkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., and van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11 (2005) 1170-1172
14. Ferrer M., Kapoor T.M., Strassmaier T., Weissenhorn W., Skehel J.J., Oprian D., Schreiber S.L., Wiley D.C., and Harrison S.C. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 6 (1999) 953-960
15. Frey G., Rits-Volloch S., Zhang X.Q., Schooley R.T., Chen B., and Harrison S.C. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 13938-13943
16. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell J.M., Lazzarin A., Vittecoq D., Gonzalez C.J., Chen J., Harvey C.M., and Isaacs R.D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369 (2007) 1261-1269
17. Hazuda D.J., Young S.D., Guare J.P., Anthony N.J., Gomez R.P., Wai J.S., Vacca J.P., Handt L., Motzel S.L., Klein H.J., Dornadula G., Danovich R.M., Witmer M.V., Wilson K.A., Tussey L., Schleif W.A., Gabryelski L.S., Jin L., Miller M.D., Casimiro D.R., Emini E.A., and Shiver J.W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305 (2004) 528-532
18. Huang J.H., Liu Z.Q., Liu S., Jiang S., and Chen Y.H. Identification of the HIV-1 gp41 core-binding motif-HXXNPF. FEBS Lett. 580 (2006) 4807-4814
19. Huang J.H., Yang H.W., Liu S., Li J., Jiang S., and Chen Y.H. The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. Biochem. J. 403 (2007) 565-571
20. Jahn R., Lang T., and Südhof T.C. Membrane fusion. Cell 112 (2003) 519-533
21. Jiang S., Lin K., Zhang L., and Debnath A.K. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods 80 (1999) 85-96
22. Kikuchi Y., Yoda K., Yamasaki M., and Tamura G. The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) of Escherichia coli. Nucl. Acids Res. 9 (1981) 5671-5678
23. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66 (1992) 2232-2239
24. Kobe B., Center R.J., Kemp B.E., and Poumbourios P. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4319-4324
25. Kodama E.I., Kohgo S., Kitano K., Machida H., Gatanaga H., Shigeta S., Matsuoka M., Ohrui H., and Mitsuya H. 4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother. 45 (2001) 1539-1546
26. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., Walmsley S., Cohen C., Kuritzkes D.R., Eron Jr. J.J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., and Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348 (2003) 2175-2185
27. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., Katlama C., Stellbrink H.J., Delfraissy J.F., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., and Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348 (2003) 2186-2195
28. Liu S., Jing W., Cheung B., Lu H., Sun J., Yan X., Niu J., Farmar J., Wu S., and Jiang S. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282 (2007) 9612-9620
29. Liu S., Lu H., Niu J., Xu Y., Wu S., and Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280 (2005) 11259-11273
30. Medinas R.J., Lambert D.M., and Tompkins W.A. C-terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. J. Virol. 76 (2002) 9079-9086
31. Mink M., Mosier S.M., Janumpalli S., Davison D., Jin L., Melby T., Sista P., Erickson J., Lambert D., Stanfield-Oakley S.A., Salgo M., Cammack N., Matthews T., and Greenberg M.L. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79 (2005) 12447-12454
32. Nameki D., Kodama E., Ikeuchi M., Mabuchi N., Otaka A., Tamamura H., Ohno M., Fujii N., and Matsuoka M. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 79 (2005) 764-770
33. Otaka A., Nakamura M., Nameki D., Kodama E., Uchiyama S., Nakamura S., Nakano H., Tamamura H., Kobayashi Y., Matsuoka M., and Fujii N. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl. 41 (2002) 2937-2940
34. Poveda E., Rodés B., Toro C., Martín-Carbonero L., Gonzalez-Lahoz J., and Soriano V. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 16 (2002) 1959-1961
35. Rimsky L.T., Shugars D.C., and Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72 (1998) 986-993
36. Root M.J., Kay M.S., and Kim P.S. Protein design of an HIV-1 entry inhibitor. Science 291 (2001) 884-888
37. Ryu J.R., Lee J., Choo S., Yoon S.H., Woo E.R., and Yu Y.G. Development of an in vitro assay system for screening of gp41 inhibitory compounds. Mol. Cells 8 (1998) 717-723
38. Schibli D.J., and Weissenhorn W. Class I and class II viral fusion protein structures reveal similar principles in membrane fusion. Mol. Membr. Biol. 21 (2004) 361-371
39. Tagat J.R., McCombie S.W., Nazareno D., Labroli M.A., Xiao Y., Steensma R.W., Strizki J.M., Baroudy B.M., Cox K., Lachowicz J., Varty G., and Watkins R. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 47 (2004) 2405-2408
40. Watanabe S., Takada A., Watanabe T., Ito H., Kida H., and Kawaoka Y. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74 (2000) 10194-10201
41. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 (2002) 1896-1905
42. Wexler-Cohen Y., and Shai Y. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J. 21 (2007) 3677-3684
43. Xu Y., Hixon M.S., Dawson P.E., and Janda K.D. Development of a FRET assay for monitoring of HIV gp41 core disruption. J. Org. Chem. 72 (2007) 6700-6707